PTC Therapeutics Inc. (PTCT)
NASDAQ: PTCTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PTCT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $4.71B
- Forward P/E
- 17.69
- EPS (TTM)
- -$1.47
- Dividend yield
- None
- 52-week range
- 56.18 – 90.87
- Day range
- 56.18 – 58.96
- Volume / Avg
- 952.60K / 1.07M
- Beta
- —
- Shares outstanding
- 83.54M
52-week range
PTCT stock today
On Nov 20, PTCT ended the session at $56.42, shedding $1.91 (3.27%), versus the S&P 500's 3.70% decline. Shares are 37.9% below their 52-week high of $90.87, set on Jul 9, 2026 and 0.4% above the 52-week low of $56.18, near the bottom of the past year's range. PTCT is down 25.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 28.1%.
PTC Therapeutics has posted a net loss over the last twelve months (EPS of -$1.47), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About PTC Therapeutics
Company profilePTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Matthew B. Klein F.A.C.S., M.D., M.S.
- Headquarters
- Warren, NJ
- Employees
- 991
- IPO year
- 2013
- Website
- ptcbio.com
Financial highlights
Full financialsIn fiscal 2025, PTC Therapeutics generated $1.73 billion in revenue, up 114.5% from fiscal 2024. Net income was $682.6 million, for a net margin of 39.4% versus a median of -80.0% in the prior 5 years. Operating margin was 50.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.73B | $806.78M | $937.82M | $698.80M | $538.59M |
| Growth | +114.51% | -13.97% | +34.20% | +29.75% | +41.45% |
| Net income | $682.64M | $-363.30M | $-626.60M | $-559.02M | $-523.90M |
| EPS (diluted) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 |
Analyst forecast
ForecastConsensus (15 analysts)
buy
Avg. price target
$100.47+78.08%
- Strong buy 4
- Buy 9
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 29, 2026
- EPS actual vs est.
- $-0.62 vs $0.17
- Surprise
- -464.71%
PTCT news
All PTCT news- PTC Therapeutics, Inc. Announces $500.0 Million Share Repurchase ProgramNasdaq
- Why is PTC Therapeutics stock surging today?Investing.com
- Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%NasdaqNBIX, PTCT, RMTI, SIBN
- PTC Therapeutics sets $500M stock buyback planSeeking Alpha
- PTC Therapeutics Board Approves $500 Mln Share BuybackNasdaqPTCT, LEN.B
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- PTC Therapeutics (PTCT) Q3 2026 Earnings Call TranscriptNasdaq
- PTC Therapeutics, Inc. Reports Q3 2026 Total Revenue of $358 million and Raises Full-Year GuidanceNasdaq
PTC Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DNTHDianthus Therapeutics Inc. | 84.55 | -0.33% | $4.76B | vs PTCT |
| ERASErasca Inc. | 13.61 | -4.29% | $4.78B | vs PTCT |
| COGTCogent Biosciences Inc. | 26.72 | -3.69% | $4.65B | vs PTCT |
| LQDALiquidia Corporation | 54.43 | -3.88% | $4.90B | vs PTCT |
| TVTXTravere Therapeutics Inc. | 47.00 | -2.69% | $4.51B | vs PTCT |
| IONSIonis Pharmaceuticals Inc. | 26.58 | -2.35% | $4.43B | vs PTCT |
| MANEVeradermics Incorporated | 119.52 | -3.92% | $5.04B | vs PTCT |
| EWTXEdgewise Therapeutics Inc. | 39.91 | -3.07% | $4.37B | vs PTCT |
Indexes, lists and sector
PTC Therapeutics stock FAQ
What is PTC Therapeutics's stock price today?
PTCT last traded at $56.42 as of Nov 20, 4:00 PM EST, down 3.27% on the day. Prices are delayed at least 15 minutes.
Who is PTC Therapeutics's CEO?
Dr. Matthew B. Klein F.A.C.S., M.D., M.S. is the chief executive officer of PTC Therapeutics Inc., which has about 991 employees.
What is the PTCT 52-week high?
The 52-week high for PTCT is $90.87 and the 52-week low is $56.18. The stock is currently 37.9% below its high.